Welcome to our dedicated page for Oculis Holding news (Ticker: OCS), a resource for investors and traders seeking the latest updates and insights on Oculis Holding stock.
Oculis Holding AG reports news on a late-stage ophthalmology and neuro-ophthalmology pipeline focused on eye and optic-nerve disorders with unmet medical need. Company updates commonly cover OCS-01 eye drops for diabetic macular edema, Privosegtor for optic neuritis and other optic neuropathies, and Licaminlimab, a topical anti-TNFα candidate being developed for dry eye disease with a genotype-based approach.
Recurring developments include clinical-program updates, FDA and EMA regulatory interactions, scientific meeting presentations, pipeline reviews, financial results, capital-market communications, annual general meeting materials, and notifications of managerial transactions. Oculis is a Swiss biopharmaceutical company with ordinary shares traded on Nasdaq and Nasdaq Iceland under OCS.
Oculis (Nasdaq: OCS) announced that the first patient has been treated in PIONEER-1, a registrational trial of Privosegtor for acute optic neuritis (ON). PIONEER-1, part of the broader PIONEER program, evaluates Privosegtor in ON patients with and without multiple sclerosis, using functional visual outcomes.
The primary endpoint is the proportion of patients achieving at least a 15-letter gain in visual acuity at Month 3; a key secondary endpoint is change in low-contrast visual acuity at Month 3. Patients will be followed to Month 12 for long-term safety. Trial design and planned analysis are covered by an FDA Special Protocol Assessment to support a future NDA in ON, subject to positive results. Privosegtor has Breakthrough Therapy, PRIME and Orphan Drug designations for ON and showed vision and neuroprotective benefits in the Phase 2 ACUITY trial. Oculis also plans an IND submission in Q4 2026 to study Privosegtor in acute multiple sclerosis relapses.
Oculis (NASDAQ: OCS) announced the publication of notifications related to the vesting and settlement of previously granted restricted stock units (RSUs) awarded to company directors. The notifications concern RSU vests dated August 13, 2026, for directors Anthony Rosenberg, Christina Ackermann, Arshad Khanani and Robert Warner.
Oculis (Nasdaq: OCS) signed an asset purchase agreement with Accure Therapeutics to acquire all worldwide development and commercial rights to Privosegtor (ACT-01), plus a separate transaction for ACT-02, an early-stage preclinical neurology candidate. The deal will terminate Oculis’ existing license with Accure, eliminating related milestone and royalty obligations for successful indications.
Total consideration includes a $3.8 million (CHF 3.1 million) cash payment at the first closing and up to 2,050,000 Oculis ordinary shares, split between locked-up upfront shares and milestone-based earnout shares. Oculis expects to assume low single-digit royalty obligations to academic licensors. Closing of ACT-01 is expected by February 28, 2027 and ACT-02 by March 31, 2027, subject to conditions. Privosegtor is in the PIONEER registrational program for optic neuropathies and holds FDA Breakthrough Therapy, EMA PRIME, and Orphan Drug designations in the U.S. and EU for optic neuritis.
Oculis (Nasdaq/XICE: OCS) reported Q2 2026 results and pipeline progress. Cash, cash equivalents and short‑term investments were CHF 228.3 million ($282.3 million) as of June 30, 2026, with the company stating this provides cash runway into the second half of 2029. For the six months ended June 30, 2026, Oculis reported a net loss of CHF 38.8 million versus CHF 58.6 million a year earlier, helped by a fair value gain on warrant liabilities and favorable foreign exchange.
The company highlighted its pivot to neuro‑ophthalmology, positioning Privosegtor as its lead late‑stage asset in the registrational PIONEER-1 trial in optic neuritis, with global site activation ongoing. FDA neurology guidance indicated no additional preclinical studies are required ahead of an IND for Privosegtor in acute multiple sclerosis (MS) relapses, and Oculis is targeting an IND submission in Q4 2026. The genotype‑based registrational PREDICT‑1 trial of Licaminlimab in dry eye disease has all planned sites activated and more than 45% of patients randomized, with topline results expected around year‑end. Oculis does not currently plan to pursue an FDA filing for OCS‑01 in diabetic macular edema following recent DIAMOND data.
Oculis (Nasdaq/XICE: OCS) reported positive U.S. FDA Division of Neurology pre-IND feedback supporting its development strategy for Privosegtor in treating acute multiple sclerosis (MS) relapses, an area with no approved neuroprotective therapies. The FDA confirmed that existing Privosegtor data can be cross‑referenced and that no additional preclinical studies are required for an IND in acute MS relapses.
According to Oculis, the FDA also backed the proposed clinical plan, including enrollment of MS patients with optic neuritis and other relapse types, a primary endpoint at 3 months, and the same 3mg/kg daily dose for 5 days used in PIONEER‑1. Oculis expects to submit the new IND in Q4 2026 and will detail this program and its ongoing registrational PIONEER trials in optic neuropathies at a virtual R&D Day in Q4 2026.
Oculis (OCS) reported a managers' transaction involving the vesting and settlement of restricted stock units (RSUs) previously granted to a company director. The notification concerns Riad Sherif and relates to an RSU vesting event dated 5 July 2026.
Oculis (Nasdaq: OCS) will participate in the Piper Sandler Virtual Ophthalmology Conference on July 10, 2026, at 9:30 a.m. ET.
Management plans to discuss late-stage programs including Privosegtor, which holds FDA Breakthrough Therapy and EMA PRIME designations for optic neuritis, and Licaminlimab, in a registrational trial for genotype-based precision treatment in dry eye disease.
Oculis (OCS) announced the publication of a notification of transactions by a person discharging managerial responsibilities. The attached notification concerns the purchase of ordinary shares by a member of the company’s Executive Committee on June 10, 2026.
Oculis (Nasdaq:OCS) will present Privosegtor at Clinical Trials at the Summit 2026 in Las Vegas on June 13, 2026, at 5:52 PM PDT.
CEO Riad Sherif will discuss Privosegtor’s development from discovery through Phase 2 ACUITY to the PIONEER registrational trials in optic neuritis and other optic neuropathies.
Oculis (OCS)/b) published notifications on June 10, 2026 regarding transactions by persons discharging managerial responsibilities.The notifications concern the vesting and settlement of previously granted RSUs to company directors on June 6, 2026, including Arshad Khanani and Riad Sherif.